The BioCentury Show
Duración total:
22 h 44 min
Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient
The BioCentury Show
29:57
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
The BioCentury Show
32:38
Ep. 115 - Initiate's Owens on what it takes to be AI-native
The BioCentury Show
40:29
Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model
The BioCentury Show
41:59
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
The BioCentury Show
35:06
Ep. 112 - Chris Arendt on rebuilding Takeda for AI
The BioCentury Show
40:29
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
The BioCentury Show
36:55
Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China
The BioCentury Show
37:37
Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
The BioCentury Show
36:08
Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
The BioCentury Show
33:21
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
The BioCentury Show
37:40
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
The BioCentury Show
33:50
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
The BioCentury Show
39:32
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
The BioCentury Show
35:14
Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development
The BioCentury Show
40:58
Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs
The BioCentury Show
40:43
Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms
The BioCentury Show
29:23
Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next
The BioCentury Show
36:45
Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma
The BioCentury Show
37:59
Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw
The BioCentury Show
37:38
Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
The BioCentury Show
38:39
Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science
The BioCentury Show
34:11
Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook
The BioCentury Show
32:17
Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem
The BioCentury Show
31:33
Ep. 94 - Frazier's James Li on China’s Rapidly Evolving Biotech Deal Landscape
The BioCentury Show
29:45
Ep. 93 – BIO’s Fritz Bittenbender on Trump 2.0, MFN Threats & Pharma’s Concessions
The BioCentury Show
34:03
Ep. 92 - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
The BioCentury Show
38:43
Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech
The BioCentury Show
36:07
Popular Episode - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
The BioCentury Show
32:44
Ep. 90 – Inside Biopharma Dealmaking: ProFound CEO John Lepore on Knowing What Partners Want
The BioCentury Show
33:05
Ep. 89 - Delivering on the biosimilars promise, a conversation with Gillian Woollett
The BioCentury Show
31:47
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity
The BioCentury Show
30:41
Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies
The BioCentury Show
27:41
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise
The BioCentury Show
10:22
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
The BioCentury Show
32:39
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
The BioCentury Show
29:19
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
The BioCentury Show
31:54
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
The BioCentury Show
31:01
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
The BioCentury Show
30:52
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
The BioCentury Show
32:26
